HDAC2 and chronic myelogenous leukemia, BCR-ABL1 positive: Taken together, the above findings potently indicate that CAY10683 combined with IM treatment induced cell cycle arrest in the G2/M phase of CML cells resistant to IM mainly through inhibiting HDAC2.